Why is Marksans Pharma Ltd ?
1
High Management Efficiency with a high ROE of 15.51%
2
Company has a low Debt to Equity ratio (avg) at 0 times
3
Poor long term growth as Operating profit has grown by an annual rate 17.78% of over the last 5 years
4
The company has declared Positive results for the last 3 consecutive quarters
- PAT(Latest six months) At Rs 298.48 cr has Grown at 90.64%
- ROCE(HY) Highest at 20.46%
- PBDIT(Q) Highest at Rs 214.29 cr.
5
Stock is technically in a Mildly Bullish range
- Multiple factors for the stock are Bullish like MACD, KST and OBV
6
With ROE of 16.8, it has a Expensive valuation with a 4 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 50.76%, its profits have risen by 59.2% ; the PEG ratio of the company is 0.4
7
High Institutional Holdings at 24.6%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 0.94% over the previous quarter.
How much should you hold?
- Overall Portfolio exposure to Marksans Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Marksans Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Marksans Pharma
50.76%
1.11
45.56%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
19.38%
EBIT Growth (5y)
17.78%
EBIT to Interest (avg)
29.11
Debt to EBITDA (avg)
0.45
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
0.99
Tax Ratio
24.65%
Dividend Payout Ratio
9.53%
Pledged Shares
0
Institutional Holding
24.60%
ROCE (avg)
24.40%
ROE (avg)
15.51%
Valuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
40
Price to Book Value
3.97
EV to EBIT
18.55
EV to EBITDA
16.05
EV to Capital Employed
4.70
EV to Sales
3.71
PEG Ratio
0.40
Dividend Yield
0.31%
ROCE (Latest)
25.36%
ROE (Latest)
16.80%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Bullish
Technical Movement
20What is working for the Company
PAT(Latest six months)
At Rs 298.48 cr has Grown at 90.64%
ROCE(HY)
Highest at 20.46%
PBDIT(Q)
Highest at Rs 214.29 cr.
CASH AND CASH EQUIVALENTS(HY)
Highest at Rs 1,061.27 cr
NET SALES(Q)
Highest at Rs 940.17 cr
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Marksans Pharma
Profit After Tax (PAT) - Latest six months
At Rs 298.48 cr has Grown at 90.64%
Year on Year (YoY)MOJO Watch
PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 214.29 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term Operating Profit trend is quite positive
Operating Profit (Rs Cr)
Net Sales - Quarterly
Highest at Rs 940.17 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Cash and Cash Equivalents - Half Yearly
Highest at Rs 1,061.27 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents